GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Analysis AS (XSAT:GEAN.TO.2) » Definitions » Revenue per Share

Genetic Analysis AS (XSAT:GEAN.TO.2) Revenue per Share : kr0.00 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Genetic Analysis AS Revenue per Share?

Genetic Analysis AS's revenue per share for the three months ended in Dec. 2023 was kr0.00. Genetic Analysis AS's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.00.

Warning Sign:

Genetic Analysis AS revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue Per Share Growth Rate of Genetic Analysis AS was -17.50% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 17.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Genetic Analysis AS's Revenue per Share or its related term are showing as below:

XSAT:GEAN.TO.2' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 15.4   Med: 16.2   Max: 17
Current: 17

During the past 5 years, Genetic Analysis AS's highest 3-Year average Revenue Per Share Growth Rate was 17.00% per year. The lowest was 15.40% per year. And the median was 16.20% per year.

XSAT:GEAN.TO.2's 3-Year Revenue Growth Rate is ranked better than
74% of 200 companies
in the Medical Diagnostics & Research industry
Industry Median: 6.2 vs XSAT:GEAN.TO.2: 17.00

Genetic Analysis AS Revenue per Share Historical Data

The historical data trend for Genetic Analysis AS's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Analysis AS Revenue per Share Chart

Genetic Analysis AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
- - - - -

Genetic Analysis AS Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Genetic Analysis AS's Revenue per Share

For the Diagnostics & Research subindustry, Genetic Analysis AS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Analysis AS's PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's PS Ratio distribution charts can be found below:

* The bar in red indicates where Genetic Analysis AS's PS Ratio falls into.



Genetic Analysis AS Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Genetic Analysis AS's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=14.147/0
=

Genetic Analysis AS's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )=Revenue (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=3.799/0
=

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetic Analysis AS  (XSAT:GEAN.TO.2) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Genetic Analysis AS Revenue per Share Related Terms

Thank you for viewing the detailed overview of Genetic Analysis AS's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Analysis AS (XSAT:GEAN.TO.2) Business Description

Traded in Other Exchanges
Address
Kabelgata 8, Oslo, NOR, 0580
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering innovative diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Genetic Analysis AS (XSAT:GEAN.TO.2) Headlines

No Headlines